Legal & General Group
SION

Legal & General Group’s Sionna Therapeutics SION Stock Holding History

Legal & General Group’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$57.4K Sell
1,432
-250
-15% -$9.54K ﹤0.01% 2657
2025
Q4 		$69.2K Sell
1,682
-5,692
-77% -$216K ﹤0.01% 2671
2025
Q3 		$217K Buy
7,374
+6,000
+437% +$131K ﹤0.01% 2581
2025
Q2 		$23.8K Buy
+1,374
New +$18K ﹤0.01% 2937

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Legal & General Group's SION Position: Q1 2026 in Review

Legal & General Group reduced its Sionna Therapeutics (SION) stake by 15% in Q1 2026, selling an estimated $9.54K and leaving 1,432 shares worth $57.4K. The position accounts for ﹤0.01% of the portfolio, ranked #2657.

Legal & General Group first reported a position in SION in Q2 2025 and has held it in 4 quarters since. The position peaked at $217K in Q3 2025. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Legal & General Group held 1,432 shares of Sionna Therapeutics worth $57.4K as of Q1 2026.
  • Legal & General Group sold 250 Sionna Therapeutics shares in Q1 2026, an estimated $9.54K.
  • Sionna Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2657 holding.
  • Legal & General Group first reported a position in Sionna Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Legal & General Group's Sionna Therapeutics position peaked at $217K in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.